Mary Cerni, DO
Adult Medicine · Placentia, CANPI 1164519989
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 184 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $983 and has fallen 87.3% since, to $125 in 2025.
Across 184 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$688
- Lilly USA, LLC$414
- Pfizer$333
- Johnson & Johnson$320
- AstraZeneca$306
- Boehringer Ingelheim$303
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,36398%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 33 | $688 |
| Lilly USA, LLC | 16 | $414 |
| Pfizer | 34 | $333 |
| Johnson & Johnson | 14 | $320 |
| AstraZeneca | 16 | $306 |
| Boehringer Ingelheim | 17 | $303 |
| Novo Nordisk | 14 | $258 |
| AbbVie(2 entities) | 8 | $149 |
| E.r. Squibb & Sons, L.L.C. | 8 | $143 |
| Nova Eye, Inc. | 1 | $125 |
| Abbott | 7 | $125 |
| Mylan Specialty L.p. | 3 | $44 |
| Merck | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $35 |
| Therapeuticsmd, Inc. | 2 | $29 |
| AMAG Pharmaceuticals, Inc. | 2 | $29 |
| Exact Sciences | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Astellas Pharma US Inc | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,437 in reported general payments places this provider in the 85th percentile of 221 adult medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $88,058 |
| JardianceEmpagliflozin | 42 | $43,581 |
| RybelsusSemaglutide | 20 | $31,652 |
| EliquisApixaban | 31 | $26,677 |
| JanuviaSitagliptin Phosphate | 19 | $21,647 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $12,757 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $10,711 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 92 | $3,805 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 95 | $2,778 |
| Rosuvastatin Calcium | 126 | $2,557 |
| Levothyroxine Sodium | 187 | $2,482 |
| Losartan Potassium | 162 | $2,209 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 15 | $2,037 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 11 | $1,964 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,656 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $258 | $119,71082 claims |
| Boehringer IngelheimJardiance | $303 | $43,58142 claims |
| PfizerEliquis | $333 | $26,67731 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $688 | $23,46849 claims |
| MerckJanuvia | $35 | $21,64719 claims |
| Lilly USA, LLCHumulin 70-30 | $414 | $2,03715 claims |
| AbbVieSynthroid | $149 | $81622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 221 adult medicine providers in California.
Other adult medicine in Placentia
- Susan HutchinsonLaguna Hills$1M
- Natalia GuzmanLos Angeles$583K
- Richard FauselRancho Mirage$30K
- Benedicto EstoestaValley Springs$22K
- Antoine DipsiaW. Sacramento$21K
- Patrick WelchArroyo Grande$20K
- Craig BobsonManteca$19K
- Tin WongLos Angeles$18K
- Sofia VaismanWoodland Hills$13K
- Janja ViltuznikOrange$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.